Osteoporosis is a detrimental disorder of bone that puts patients at increased risk of pathologic fractures. Patients with cerebral palsy (CP), due to a multitude of factors, are at increased risk of developing this disorder. Studies in the past have looked at various treatment options for these patients to reduce and/or prevent pathologic fractures. Most studies have looked into the use of bisphosphonates for prevention. Teriparatide is a recombinant PTH analog that has been shown to increase bone mineral density and reduce fragility fractures in adults with non- CP related osteoporosis. Despite the reduction seen in these studies, empirical evidence for the use of PTH analogs in CP related osteoporosis is scarce. PTH analogs, like Teriparatide, have shown to be beneficial in patients with non-CP related osteoporosis, further studies need to be performed to assess its benefit for patients with CP related osteoporosis.
Patrisha Shelley, Linda Edwards and Rafik Jacob